Irem Bilgetekin

8PUBLICATIONS
96CO-AUTHORS
Innate immunityMolecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 26, 2026
Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.

|Jun 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

|Jun 24, 2026
The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancer.

|Mar 12, 2026
Renal schwannoma appears on imaging as renal cell carcinoma: a case report.

Zeynep Akdagcik, Irem Bilgetekin, Erdem Ozturk

|Feb 27, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

Baris Koksal, Hasan Cagri Yildirim, Deniz Can Guven

|Aug 03, 2021
Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.

Cengiz Karacin, Tulay Eren, Esra Zeynelgil

Pageof 2

Frequent Collaborators

2 joint publications

Ozkan Alan

2 joint publications

Banu Ozturk

2 joint publications

Deniz Can Guven

2 joint publications

Cengiz Karacin